Insider Buying: Perspective Therapeutics (NYSEAMERICAN:CATX) Director Acquires $15,631.56 in Stock

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) Director Robert Williamson III bought 18,609 shares of the company’s stock in a transaction on Thursday, November 12th. The stock was purchased at an average cost of $0.84 per share, for a total transaction of $15,631.56. Following the completion of the transaction, the director owned 28,473 shares in the company, valued at approximately $23,917.32. The trade was a 188.66% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Perspective Therapeutics Price Performance

CATX opened at $0.94 on Monday. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01. Perspective Therapeutics, Inc. has a fifty-two week low of $0.78 and a fifty-two week high of $6.16. The business has a 50-day moving average of $2.11 and a 200-day moving average of $3.44.

Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.06 million. Perspective Therapeutics had a negative return on equity of 42.25% and a negative net margin of 55,866.82%. Equities research analysts anticipate that Perspective Therapeutics, Inc. will post -1.01 EPS for the current year.

Analysts Set New Price Targets

Several research firms have commented on CATX. Piper Sandler decreased their target price on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Royal Bank Of Canada downgraded shares of Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price target for the company from $14.00 to $4.00 in a report on Monday, October 26th. Wedbush reissued an “outperform” rating and set a $7.00 target price (down from $9.00) on shares of Perspective Therapeutics in a research report on Tuesday, November 10th. BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a report on Monday, October 26th. Finally, William Blair began coverage on Perspective Therapeutics in a research report on Friday, September 18th. They issued an “outperform” rating for the company. Nine analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Perspective Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $10.10.

View Our Latest Analysis on Perspective Therapeutics

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its position in shares of Perspective Therapeutics by 391.6% in the first quarter. Dimensional Fund Advisors LP now owns 450,097 shares of the company’s stock valued at $1,877,000 after purchasing an additional 358,540 shares during the period. Avidity Partners Management LP lifted its stake in shares of Perspective Therapeutics by 88.4% in the first quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock worth $25,228,000 after buying an additional 2,839,266 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Perspective Therapeutics in the first quarter worth $1,581,000. Yu Fan bought a new stake in shares of Perspective Therapeutics during the 1st quarter worth $4,401,000. Finally, Commodore Capital LP bought a new stake in shares of Perspective Therapeutics during the 1st quarter worth $26,424,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

(Get Free Report)

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.

Recommended Stories

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.